InVivo Temporarily Fills CFO Seat
InVivo Therapeutics Holdings Corp. has replaced its chief financial officer (CFO), who left his post after only two weeks on the job. Currently serving as interim CFO will be Gregory D. Perry, formerly executive vice president and CFO of Immunogen Inc., a company that licenses tumor-activated pro-drug technology for development of small molecule anticancer agents.
Prior to joining Immunogen, Perry served as CFO of Elixir Pharmaceuticals Inc. from 2007 to 2009. Prior to Elixir, he was CFO of Domantis Ltd., which was acquired by GlaxoSmithKline in 2006. Previously, Perry was senior vice president and CFO of Transkaryotic Therapies Inc. until its acquisition by Shire plc in 2005. Perry is currently a member of the Board of Directors of Advanced Cell Technology Inc.
“We are excited to bring on board a CFO with the integrity, talent and experience of Greg Perry,” said Mike Astrue, the interim CEO of InVivo. “His breadth of experience can add value to InVivo in a variety of ways.”
Astrue served as interim CFO during the search for a replacement.
InVivo Therapeutics Holdings Corp. focuses on polymer-based platform technology to develop treatments for traumatic spine and brain injury. The company is based in Cambridge, Mass.